Metagenomi Therapeutics Statistics
Total Valuation
MGX has a market cap or net worth of $46.47 million. The enterprise value is -$36.48 million.
| Market Cap | 46.47M |
| Enterprise Value | -36.48M |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MGX has 37.78 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 37.65M |
| Shares Outstanding | 37.78M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 10.50% |
| Owned by Institutions (%) | 18.01% |
| Float | 25.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.45 |
| Forward PS | 4.11 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 0.34.
| Current Ratio | 4.50 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.61% and return on invested capital (ROIC) is -32.31%.
| Return on Equity (ROE) | -60.61% |
| Return on Assets (ROA) | -28.19% |
| Return on Invested Capital (ROIC) | -32.31% |
| Return on Capital Employed (ROCE) | -68.85% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | $114,924 |
| Profits Per Employee | -$792,051 |
| Employee Count | 118 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -190,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.57% in the last 52 weeks. The beta is 0.67, so MGX's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -34.57% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 49.99 |
| Average Volume (20 Days) | 142,677 |
Short Selling Information
The latest short interest is 1.54 million, so 4.09% of the outstanding shares have been sold short.
| Short Interest | 1.54M |
| Short Previous Month | 1.68M |
| Short % of Shares Out | 4.09% |
| Short % of Float | 6.07% |
| Short Ratio (days to cover) | 7.76 |
Income Statement
In the last 12 months, MGX had revenue of $13.56 million and -$93.46 million in losses. Loss per share was -$2.49.
| Revenue | 13.56M |
| Gross Profit | -57.09M |
| Operating Income | -100.57M |
| Pretax Income | -93.65M |
| Net Income | -93.46M |
| EBITDA | -95.40M |
| EBIT | -100.57M |
| Loss Per Share | -$2.49 |
Balance Sheet
The company has $120.66 million in cash and $37.72 million in debt, with a net cash position of $82.94 million or $2.20 per share.
| Cash & Cash Equivalents | 120.66M |
| Total Debt | 37.72M |
| Net Cash | 82.94M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 112.57M |
| Book Value Per Share | 2.98 |
| Working Capital | 96.84M |
Cash Flow
In the last 12 months, operating cash flow was -$85.49 million and capital expenditures -$309,000, giving a free cash flow of -$85.80 million.
| Operating Cash Flow | -85.49M |
| Capital Expenditures | -309,000 |
| Depreciation & Amortization | 5.16M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.80M |
| FCF Per Share | -$2.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | -741.58% |
| Pretax Margin | -690.60% |
| Profit Margin | n/a |
| EBITDA Margin | -703.50% |
| EBIT Margin | -741.58% |
| FCF Margin | n/a |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -199.52% |
| FCF Yield | -183.15% |
Analyst Forecast
The average price target for MGX is $7.00, which is 469.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 469.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -17.42% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |